Objective: To evaluate the predicting value of technetium-99m-sestambi (99mTc-MIBI) scintigraphy in the assessment of histological response to neoadjuvant chemotherapy in patients with osteosarcomas. Methods: A detailed search was made in Web of Science, PubMed, Elsevier, China National Knowledge Infrastructure (CNKI), Wanfang database for relevant original articles published in English or Chinese, up to April 2020; methodological quality of the included studies were also assessed. Two reviewers extracted data. Sufficient data were presented to construct a 2×2 contingency table. Pooled sensitivity, specificity were estimated. A summary receiver operating characteristic curve(ROC curve) was constructed. A χ2 test was performed to test for heterogeneity. The Der Simonian and Laird random effect model was applied if significant heterogeneity between studies was observed, while a fixed effect model was used in the absence of significant between-study heterogeneity. Results: Eight studies met the inclusion criteria. Six studies searched the relationship between alteration uptake ratio(AUR) and tumor necrosis ratio(TNR), including 134 patients. The pooled sensitivity, specificity and area under the ROC curve(AUC) for AUR ≥ 30% were 0.85(95%CI:0.74-0.93), 0.59(95%CI:0.47-0.70) and 0.84;for AUR ≥ 35% were 0.91(95%CI:0.79-0.98),0.68(95%CI:0.55-0.79) and 0.87;for AUR ≥ 38% were 0.87(95%CI:0.72-0.96), 0.80(95%CI:0.66-0.89) and 0.91, respectively. There were four studies revealing the relationship between washout rate(WR) and TNR, including 96 patients. The pooled sensitivity, specificity and AUC for WR ≤ 22% were 0.57(95%CI:0.37-0.75), 0.94(95%CI:0.85-0.98) and 0.90;for WR ≤ 25% were 0.70(95% CI:0.51-0.85), 0.86(95%CI:0.76-0.94) and 0.87, respectively. Conclusion: 99mTc-MIBI imaging, especially using AUR ≥ 38% and WRAUR ≤ 25% as cut-off values, can early and non-invasively predict histological response after neoadjuvant chemotherapy in osteosarcoma, and the predictive ability of AUR ≥ 38% is better than that of WRAUR ≤ 25%. |
[1] DAVIS A M,BELL R S,GOODWIN P J.Prognostic factors in osteosarcoma:a critical review[J].J Clin Oncol,1994,12(2):423-431.
[2] KUBO T,FURUTA T,JOHAN M P,et al.Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma:systematic review and meta-analysis[J].Skeletal Radiol,2016,45(9):1235-1242.
[3] KUBO T,FURUTA T,JOHAN M P,et al.Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma:a meta-analysis[J].Mol Clin Oncol,2017,7(1):88-92.
[4] HONGTAO L,HUI Z,BINGSHUN W,et al.18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas:a meta-analysis[J].Surg Oncol,2012,21(4):e165-e170.
[5] KUBO T,SHIMOSE S,FUJIMORI J,et al.Quantitative201thallium scintigraphy for prediction of histological response to neoadjuvant chemotherapy in osteosarcoma:systematic review and meta-analysis[J].Surg Oncol,2015,24(3):194-199.
[6] 黄中柯.99mTc-MIBI显像对骨肉瘤新辅助化疗效果评估的临床价值[D].杭州:浙江大学,2019.
[7] LING V.Multidrug resistance:molecular mechanisms and clinical relevance[J].Cancer Chemother Pharmacol,1997,40(l):S3-S8.
[8] GOTTESMAN M M,PASTAN I.Biochemistry of multidrug resistance mediated by the multidrug transporter[J].Annu Rev Biochem,1993,62:385-427.
[9] CHAN H S,GROGAN T M,HADDAD G,et al.P-glycoprotein expression:critical determinant in the response to osteosarcoma chemotherapy[J].J Natl Cancer Inst,1997,89(22):1706-1715.
[10] VERGOTE J,MORETTI J L,DE VRIES E G,et al.Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes[J].Eur J Biochem,1998,252(1):140-146.
[11] KAPUCU L O,AKYVZ C,VURAL G,et al.Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi[J].J Nucl Med,1997,38(2):243-247.
[12] BURAK Z,YVKSEL D A,CETINGVL N,et al.The role of 99mTc-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma:comparison with131I-MIBG and 99mTc-MDP scintigraphy[J].Nucl Med Commun,1999,20(11):991-1000.
[13] SASAKI M,KUWABARA Y,ICHIYA Y,et al.Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT[J].J Nucl Med,1999,40(11):1778-1783.
[14] CIARMIELLO A,DEL VECCHIO S,SILVESTRO P,et al.Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer[J].J Clin Oncol,1998,16(5):1677-1683.
[15] TAKI J,SUMIYA H,ASADA N,et al.Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy[J].J Nucl Med,1998,39(7):1179-1184.
[16] SALZER-KUNTSCHIK M,DELLING G,BERON G,et al.Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80[J].J Cancer Res Clin Oncol,1983,106(l):21-24.
[17] 王媛媛,秦刚,汪徐林,等.GetData Graph Digitizer软件在生存分析中的应用[J].中国卫生统计,2016,33(2):339-342.
[18] WHITING P F,RUTJES A W,WESTWOOD M E,et al.QUADAS-2:a revised tool for the quality assessment of diagnostic accuracy studies[J].Ann Intern Med,2011,155(8):529-536.
[19] SÖDERLUND V,LARSSON S A,BAUER H C,et al.Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy[J].Eur J Nucl Med,1997,24(5):511-515.
[20] BURAK Z,MORETTI J L,ERSOY O,et al.99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression[J].J Nucl Med,2003,44(9):1394-1401.
[21] MIWA S,SHIRAI T,TAKI J,et al.Use of 99mTc-MIBI scintigraphy in the evaluation of the response to chemotherapy for osteosarcoma:comparison with 201Tl scintigraphy and angiography[J].Int J Clin Oncol,2011,16(4):373-378.
[22] SOHAIB M,WIQAR M A,ALI M K,et al.A single 99mTc-MIBI study to predict response to neoadjuvant treatment in sarcoma patiens[J].Hell J Nucl Med,2011,14(2):140-145.
[23] 黄中柯,楼岑,史国华.201TI和99mTC-MIBI显像定量分析在骨肉瘤新辅助化疗中的价值[J].浙江大学学报(医学版),2012,41(2):183-187.
[24] GHAREHDAGHI M,DABBAGH K V,KHOOEI A,et al.Is 99mTc-MIBI scintigraphy a predictor of response to preoperative neoadjuvant chemotherapy in osteosarcoma?[J].Asia Ocean J Nucl Med Biol,2013,1(2):22-27.
[25] WAKABAYASHI H,SAITO J,TAKI J,et al.Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma:comparison with 99mTc-MIBI scintigraphy[J].Skeletal Radiol,2016,45(1):87-95.
[26] WU C,WANG Q,LI Y.Prediction and evaluation of neoadjuvant chemotherapy using the dual mechanisms of 99mTc-MIBI scintigraphy in patients with osteosarcoma[J].J Bone Oncol,2019,17:100250.
[27] WU F,HUANG Y,HUANG X,et al.99mTc-MIBI scintigraphy for the preoperative assessment of histological response to neoadjuvant chemotherapy in patients with osteosarcoma:a systematic review and a bivariate meta-analysis[J].Front Oncol,2020,10:762. |